

Ph. Eur. Monograph 2918: Test for Everolimus Impurity A on Kinetex® 2.7 µm C18

Zeshan Aqeel¹ and Heiko Behr²

¹Phenomenex Inc., 411 Madrid Ave., Torrance, CA 90501 1430, USA

²Phenomenex Ltd. Deutschland, Zeppelinstr. 5, 63741 Aschaffenburg, Germany

Overview

Everolimus is an immunosuppressant used to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumors.

In this application note we demonstrate the separation of Everolimus from Sirolimus (Impurity A) according to Ph. Eur. Monograph 2918 for the determination of Impurity A.

The chromatogram obtained for reference solution (a) was used to confirm the retention time for Impurity A. Three batches of the Kinetex 2.7 µm C18 column were used to demonstrate excellent batch-to-batch reproducibility, with each column meeting the system suitability requirement for the separation between Impurity A and Everolimus, as determined by the peak-to-valley ratio (minimum 2.0); where H_p = height above the baseline of the peak due to Impurity A and H_v = height above the baseline of the lowest point of the curve separating this peak from the peak due to Everolimus.

All reference solutions were prepared as indicated in Ph. Eur. monograph 2918 for Everolimus. (NOTE: Plastic labware was not used for solution preparation, as recommended, to minimize the formation of the everolimus tautomer; therefore the observed peak for the tautomer was significantly larger than expected). The Everolimus (catalog no. Y0002048) certified reference standard (CRS) was purchased from the European Directorate for the Quality of Medicines & HealthCare (EDQM) Council of Europe; and the Sirolimus (Impurity A) reference standard (catalog no. 1612765) was obtained from US Pharmacopeia (USP).

LC-UV Conditions

Column: Kinetex 2.7 µm C18

Dimension: 150 x 2.1 mm (00F-4783-AN)

Mobile Phase: A = Formic acid/Methanol/0.7 g/L Ammonium Formate/Acetonitrile (0.05:100:450:450 v/v/v/v)

B = Formic acid/Methanol/0.96 g/L Ammonium Formate/Acetonitrile (0.05:100:330:570 v/v/v/v)

Gradient: Time (min)	% B
0	0
14	0
23	100
28	100
30	0
34	0

Flow Rate: 0.9 mL/min

Temperature: 60 °C

Detector: UV @ 278 nm

Injection: 3.5 µL

System: Waters® ACQUITY® I-Class


Sample: 1. Sirolimus (Impurity A)
2. Everolimus
3. Everolimus Tautomer

Table 1: Preparation of Test and Reference Solutions


Solution	Composition
Test Solution	Dissolve 50.0 mg of Everolimus CRS (or the substance to be examined) in acetonitrile and dilute to 25.0 mL with acetonitrile.
Reference solution (a)	Dissolve 1 mg of USP Sirolimus RS (impurity A) in 5 mL of acetonitrile. Dilute 0.8 mL of the solution to 10 mL with the test solution.




Original chromatogram published in EDQM for reference solution (a)




Kinetex® 2.7 µm C18 150 x 2.1 mm (00F-4783-AN); reference solution (a) on 3 different batches



$H_{p,r}$ (Impurity A)	$H_{v,r}$ (Everolimus)	$p/v = H_v/H_p$
17458	5668	3.08



$H_{p,r}$ (Impurity A)	$H_{v,r}$ (Everolimus)	$p/v = H_v/H_p$
17299	5751	3.01



$H_{p,r}$ (Impurity A)	$H_{v,r}$ (Everolimus)	$p/v = H_v/H_p$
17141	5470	3.13



Need a different column size or sample preparation format?

No problem! We have a majority of our available dimensions up on www.phenomenex.com, but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal www.phenomenex.com/LiveChat.

Australia

t: +61 (0)2-9428-6444
auinfo@phenomenex.com

Austria

t: +43 (0)1-319-1301
anfrage@phenomenex.com

Belgium

t: +32 (0)2 503 4015 (French)
t: +32 (0)2 511 8666 (Dutch)
beinfo@phenomenex.com

Canada

t: +1 (800) 543-3681
info@phenomenex.com

China

t: +86 400-606-8099
cninfo@phenomenex.com

Czech Republic

t: +420 272 017 077
cz-info@phenomenex.com

Denmark

t: +45 4824 8048
nordicinfo@phenomenex.com

Finland

t: +358 (0)9 4789 0063
nordicinfo@phenomenex.com

France

t: +33 (0)1 30 09 21 10
franceinfo@phenomenex.com

Germany

t: +49 (0)6021-58830-0
anfrage@phenomenex.com

Hong Kong

t: +852 6012 8162
hkinfo@phenomenex.com

India

t: +91 (0)40-3012 2400
indiainfo@phenomenex.com

Ireland

t: +353 (0)1 247 5405
eirinfo@phenomenex.com

Italy

t: +39 051 6327511
italiainfo@phenomenex.com

Luxembourg

t: +31 (0)30-2418700
nlinfo@phenomenex.com

Mexico

t: 01-800-844-5226
tecnicomx@phenomenex.com

The Netherlands

t: +31 (0)30-2418700
nlinfo@phenomenex.com

New Zealand

t: +64 (0)9-4780951
nzinfo@phenomenex.com

Norway

t: +47 810 02 005
nordicinfo@phenomenex.com

Poland

t: +48 22 104 21 72
pl-info@phenomenex.com

Portugal

t: +351 221 450 488
ptinfo@phenomenex.com

Singapore

t: +65 800-852-3944
sginfo@phenomenex.com

Slovakia

t: +420 272 017 077
sk-info@phenomenex.com

Spain

t: +34 91-413-8613
espinfo@phenomenex.com

Sweden

t: +46 (0)8 611 6950
nordicinfo@phenomenex.com

Switzerland

t: +41 (0)61 692 20 20
swissinfo@phenomenex.com

Taiwan

t: +886 (0) 0801-49-1246
twinfo@phenomenex.com

Thailand

t: +66 (0) 2 566 0287
thaiinfo@phenomenex.com

United Kingdom

t: +44 (0)1625-501367
ukinfo@phenomenex.com

USA

t: +1 (310) 212-0555
info@phenomenex.com

☉ **All other countries/regions**
Corporate Office USA

t: +1 (310) 212-0555
info@phenomenex.com

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at international@phenomenex.com

BE-HAPPY™
GUARANTEE

Your happiness is our mission. Take 45 days to try our products. If you are not happy, we'll make it right.

www.phenomenex.com/behappy

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at www.phenomenex.com/TermsAndConditions.

Trademarks

Kinetex is a registered trademark and BE-HAPPY is a trademark of Phenomenex. Waters and ACQUITY are registered trademarks of Waters Technologies Corporation..

Disclaimer

Comparative separations may not be representative of all applications.

Phenomenex is in no way affiliated with Waters.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2021 Phenomenex, Inc. All rights reserved.

